Cytek Biosciences Inc. (CTKB) reported first-quarter 2026 revenue of $44.1 million, up 6.46% year-over-year, and gross profit of $21.3 million (up 5.44%).
Results came in slightly below analyst expectations, with revenue versus an estimate of $45.2 million and earnings per share versus an estimate of -$0.10.
Shares of Cytek Biosciences (CTKB) traded down 4.67% since market close following the release.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Cytek Biosciences Inc. Hedge Fund Activity
We have seen 75 institutional investors add shares of Cytek Biosciences Inc. stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BOSTON PARTNERS added 4,971,126 shares (+13369.4%) to their portfolio in Q4 2025, for an estimated $25,104,186
- BROWN CAPITAL MANAGEMENT LLC removed 2,885,101 shares (-58.2%) from their portfolio in Q4 2025, for an estimated $14,569,760
- WELLINGTON MANAGEMENT GROUP LLP removed 1,776,767 shares (-69.9%) from their portfolio in Q4 2025, for an estimated $8,972,673
- MILLENNIUM MANAGEMENT LLC added 1,334,065 shares (+39.0%) to their portfolio in Q4 2025, for an estimated $6,737,028
- RUSSELL INVESTMENTS GROUP, LTD. added 841,614 shares (+527.6%) to their portfolio in Q4 2025, for an estimated $4,250,150
- CENTERBOOK PARTNERS LP added 729,874 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,189,549
- BANK OF AMERICA CORP /DE/ added 686,001 shares (+403.2%) to their portfolio in Q4 2025, for an estimated $3,464,305
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Cytek Biosciences Inc. Government Contracts
We have seen $1,180,000 of award payments to $CTKB over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- BASE PERIOD - MAINTENANCE SERVICES FOR SIX (6) CYTEK AURORA DEVICES TO MAINTAIN OPTIMAL PERFORMANCE IN SUPP...: $233,547
- CYTEK AURORA LASER SERVICE CONTRACT -: $109,218
- MAINTENANCE/SERVICE CONTRACT FOR CYTEK AURORA FLOW CYTOMETER, S/N U0537/CD141, PRODUCT #N9-90136 (AMBIS 226...: $42,580
- PURCHASE OF AMNIS IMAGESTREAM MKII SYSTEM: $39,288
- IMAGESTREAM MKII MAINTENANCE CONTRACT COVERAGE.: $38,290
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Cytek Biosciences Inc. Analyst Ratings
Wall Street analysts have issued reports on $CTKB in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 01/08/2026
- Piper Sandler issued a "Overweight" rating on 11/11/2025
To track analyst ratings and price targets for Cytek Biosciences Inc., check out Quiver Quantitative's $CTKB forecast page.
Cytek Biosciences Inc. Price Targets
Multiple analysts have issued price targets for $CTKB recently. We have seen 2 analysts offer price targets for $CTKB in the last 6 months, with a median target of $6.25.
Here are some recent targets:
- Brendan Smith from TD Cowen set a target price of $5.0 on 01/08/2026
- David Westenberg from Piper Sandler set a target price of $7.5 on 11/11/2025
